On OX40 and PD-1 combination: Why should OX40 be first in sequence?

Research output: Contribution to journalReview article

Abstract

The larger fraction of patients treated with immune checkpoint inhibitors remain nonresponding eventually. Combination of checkpoint inhibitor and costimulatory antibodies is thought additive, but for such effect, they may require to be given in the right sequence.

Original languageEnglish
Pages (from-to)5999-6001
Number of pages3
JournalClinical Cancer Research
Volume23
Issue number20
DOIs
Publication statusPublished - Oct 15 2017

Fingerprint

Antibodies

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

On OX40 and PD-1 combination : Why should OX40 be first in sequence? / Colombo, Mario P.

In: Clinical Cancer Research, Vol. 23, No. 20, 15.10.2017, p. 5999-6001.

Research output: Contribution to journalReview article

@article{f1192c1dcd2b41829555d09412947573,
title = "On OX40 and PD-1 combination: Why should OX40 be first in sequence?",
abstract = "The larger fraction of patients treated with immune checkpoint inhibitors remain nonresponding eventually. Combination of checkpoint inhibitor and costimulatory antibodies is thought additive, but for such effect, they may require to be given in the right sequence.",
author = "Colombo, {Mario P.}",
year = "2017",
month = "10",
day = "15",
doi = "10.1158/1078-0432.CCR-17-2332",
language = "English",
volume = "23",
pages = "5999--6001",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "20",

}

TY - JOUR

T1 - On OX40 and PD-1 combination

T2 - Why should OX40 be first in sequence?

AU - Colombo, Mario P.

PY - 2017/10/15

Y1 - 2017/10/15

N2 - The larger fraction of patients treated with immune checkpoint inhibitors remain nonresponding eventually. Combination of checkpoint inhibitor and costimulatory antibodies is thought additive, but for such effect, they may require to be given in the right sequence.

AB - The larger fraction of patients treated with immune checkpoint inhibitors remain nonresponding eventually. Combination of checkpoint inhibitor and costimulatory antibodies is thought additive, but for such effect, they may require to be given in the right sequence.

UR - http://www.scopus.com/inward/record.url?scp=85031497561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031497561&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-17-2332

DO - 10.1158/1078-0432.CCR-17-2332

M3 - Review article

AN - SCOPUS:85031497561

VL - 23

SP - 5999

EP - 6001

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 20

ER -